Arovella Therapeutics Ltd (ASX: ALA) Share Price and News
Price
$0.088
Movement
0.00 (0.0)
as at 19 Nov - Closed (20 mins delayed)
52 Week Range
$0.068 - $0.205
1 Year Return
-52.43%
Arovella Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
$0.088
Day Change
0.00 (0.0)
52 Week Range
$0.068 - $0.205
Yesterday's Close
$0.088
Today's Open
$0.089
Days Range
$0.086 - $0.089
Volume
242,099
Avg. Volume (1 month)
1,214,445
Turnover
$21,114
as at 19 Nov - Closed
Arovella Therapeutics Ltd (ASX: ALA)
Latest News
Share Market News
Suda Pharmaceuticals share price soars 200% on TGA approval
ALA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| 18th Nov 2025 2025-11-18T09:39:14 | Investor Presentation | YesNo | 9:39am | 40 | 6.2M |
| 13th Nov 2025 2025-11-13T09:08:17 | Change of Director's Interest Notice | YesNo | 9:08am | 2 | 199k |
| 13th Nov 2025 2025-11-13T09:08:02 | Notice Under Section 708A | YesNo | 9:08am | 2 | 217k |
| 13th Nov 2025 2025-11-13T09:06:12 | Notification of cessation of securities - ALA | YesNo | 9:06am | 4 | 13k |
| 13th Nov 2025 2025-11-13T09:05:02 | Application for quotation of securities - ALA | YesNo | 9:05am | 6 | 16k |
| 12th Nov 2025 2025-11-12T12:44:55 | Initial Director's Interest Notice | YesNo | 12:44pm | 2 | 234k |
| 12th Nov 2025 2025-11-12T08:51:39 | Appointment of Dr Andrew Nash as Non-Executive Director | YesNo | 8:51am | 2 | 185k |
| 11th Nov 2025 2025-11-11T08:21:31 | Change of Director's Interest Notice x2 | YesNo | 8:21am | 4 | 223k |
| 11th Nov 2025 2025-11-11T08:21:26 | Notification regarding unquoted securities - ALA | YesNo | 8:21am | 6 | 17k |
| 5th Nov 2025 2025-11-05T09:45:15 | ALA Exercises Option for Baylor College of Medicine Assets | YesNo | 9:45am | 2 | 207k |
About Arovella Therapeutics Ltd
Arovella Therapeutics Ltd. develops pharmaceuticals and distributes medical devices and consumables. Its activities include pharmaceutical development of drug delivery technology and medical devices and consumables distribution. The company operates through following business segment: Suda; and Malaria Research Company. The Suda segment includes research and development to create new human pharmaceutical products by combining proven drugs with innovated, patented, delivery technologies. The Malaria Research Company segment segment is the pharmaceutical development segment for the treatment of malaria. Arovella Therapeutics was founded on December 21, 1999 and is headquartered in Osborne Park, Australia.